Navigation Links
BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
Date:1/6/2009

LYNBROOK, N.Y., Jan. 6 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (OTC Bulletin Board: BSTC), a biopharmaceutical company developing first in class collagenase based products, today announced that it has received notification from The NASDAQ Stock Market LLC that its common stock has been approved for listing on the NASDAQ Global Market. The Company's common stock will begin trading January 9, 2009 on NASDAQ at market open under the symbol "BSTC" and will end trading on the OTC Bulletin Board at the close of market on January 8, 2009.

"This listing on NASDAQ marks the culmination of a transformational year for us at BioSpecifics, and we believe it will greatly benefit our stockholders by enhancing our liquidity and overall visibility," stated Thomas L. Wegman, President of BioSpecifics. "In 2008, we announced positive Phase 3 clinical results for our collagenase product XIAFLEX(TM) for Dupuytren's disease and our partner Auxilium initiated the Phase 2b trial for Peyronie's disease. In addition, Auxilium just announced a major European licensing agreement with Pfizer, in which BioSpecifics will receive a share of both the upfront payment and sales and regulatory milestones. We are very much looking forward to further progress, including the filing with the U.S. Food and Administration of the Biologic License Application of XIAFLEX early this year."

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed and partnered, injectable collagenase for three clinical indications: Dupuytren's disease, Peyronie's disease, and frozen shoulder (adhesive capsulitis). It has a development and licensing agreement with Auxilium Pharmaceuticals, Inc. Positive top line results from the Phase III clinical trials with XIAFLEX(TM) for treatment of Dupuytren's disease were released in June 2008. Based on those positive Phase III results, Auxilium expects to file a Biologic License Application in early 2009.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioSpecifics to Present at the 9th Annual Healthcare Conference of Acumen Bio Fin Rodman Renshaw LLC
2. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
3. BioSpecifics Technologies Corp. Announces Repayment of Outstanding Loan
4. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
5. BioSpecifics Technologies Corp. Announces Additional Sales of Stock in Private Placement Offering
6. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
7. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
8. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
9. BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Fluxion Biosciences announced today that Genetracer Biotech ... appointed as a Certified Service Provider for Fluxion,s IsoFlux ... used in Genetracer Biotech,s novel liquid biopsy workflows for ... with plans to move to other cancers as additional ... System to isolate, recover, and analyze CTCs (circulating tumor ...
(Date:2/25/2017)... New York (PRWEB) , ... February 25, 2017 ... ... partnership with Verified Clinical Trials in an ongoing effort to create ... of treatment, advocacy, and pharmaceutical research with emphasis on consumers and patients’ mental ...
(Date:2/24/2017)... KNOXVILLE, Tenn. , Feb. 24, 2017 /PRNewswire/ ... ) ("Provectus" or the "Company"), a clinical-stage oncology ... information regarding the deadline to participate in its ... million units, consisting of shares of common stock ... stockholders and holders of listed warrants. ...
(Date:2/24/2017)... HONG KONG, Feb. 24, 2017 China Cord Blood ... "Company"), China,s leading provider of cord blood collection, laboratory ... services, today announced its unaudited financial results for the ... 2017 ended December 31, 2016. Third Quarter ... the third quarter of fiscal 2017 increased by 18.6% ...
Breaking Biology Technology:
(Date:2/16/2017)...  Genos, a community for personal genetic discovery ... Laboratory Accreditation from the College of American Pathologists ... that meet stringent requirements around quality, accuracy and ... "Genos is committed to maintaining the highest ... to be receiving CAP accreditation," said Jill ...
(Date:2/9/2017)... LONDON , Feb. 9, 2017 The ... in-depth analysis of the biomass boiler market globally in ... sales of biomass boilers. The market for biomass boilers ... product type, end-user, application, and country/region. The market based ... agriculture & forest residues, biogas & energy crops, urban ...
(Date:2/8/2017)... -- Report Highlights The global biosurgery market ... in 2016 at a compound annual growth rate (CAGR) ... - An overview of the global market for biosurgery. ... 2015 and 2016, and projections of compound annual growth ... on the basis of product type, source, application, and ...
Breaking Biology News(10 mins):